Clinical trials: Liver Diseases
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response.
- Trial name
- NCT04168333
- Testing
- T101 Group
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)
Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and…
- Conditions
- Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV, HCV
- Trial name
- MAGICS IBCS (NCT07170748)
- Where
- 2 sites in Côte d’Ivoire, Kenya
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- MagIA Diagnostics
Carcinoma, Hepatocellular
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Mapatumumab is a fully human, agonist monoclonal antibody that activates the cell death pathway in tumor cells by specifically binding to TRAIL-R1 with high affinity.
- Trial name
- NCT01258608
- Testing
- Mapatumumab, Sorafenib
- Where
- 43 sites in United States, Germany and 5 more
- Volunteers
- 101 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Liver Metastases, Colorectal Neoplasms
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver…
- Conditions
- Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local
- Trial name
- NCT00440310
- Testing
- Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 483 people
- Sponsor
- Light Sciences Oncology
Advanced Cancer, Gastric Adenocarcinoma
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer.
- Conditions
- Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer
- Trial name
- NCT02082210
- Testing
- Emibetuzumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Chronic Hepatitis C
Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.
- Trial name
- NCT00823862
- Testing
- SD-101, ribavirin
- Where
- 5 sites in Poland
- Volunteers
- 34 people
- Sponsor
- Dynavax Technologies Corporation
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Primary Biliary Cholangitis
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
- Trial name
- ELSPIRE (NCT06383403)
- Testing
- Elafibranor
- Where
- 60 sites in United States, Czechia and 8 more
- Volunteers
- 92 people
- Sponsor
- Ipsen
Healthy, Hepatic Insufficiency
A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function
The purpose of the study is to determine the concentration of canagliflozin in blood and urine samples after the administration of canagliflozin to study participants with mild or moderate hepatic (liver) impairment compared with…
- Trial name
- NCT01186588
- Testing
- Canagliflozin
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Infections, Human Immunodeficiency Virus and Hepatitis
Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of HIV infection.
- Trial name
- NCT01467518
- Testing
- Dolutegravir, Methadone
- Where
- Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Influenza, Human
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
The objective of this multicenter, open, single-dose, parallel controlled, Phase I clinical study is to Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver insufficiency compared with…
- Trial name
- ZX-7101A-203 (NCT05711797)
- Testing
- ZX-7101A 80mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Chronic Hepatitis C
A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C
This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the…
- Trial name
- NCT01908335
- Testing
- PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose
- Where
- 52 sites in China
- Volunteers
- 212 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Hepatitis B, Chronic Hepatitis B
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection
- Trial name
- NCT02826018
- Testing
- ALN-HBV, Sterile Normal Saline (0.9% NaCl)
- Where
- 9 sites in Australia, Hong Kong and 4 more
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Intrahepatic Cholangiocarcinoma
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Basilea provided expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical…
- Trial name
- NCT04087876
- Testing
- derazantinib
- Sponsor
- Basilea Pharmaceutica
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
- Trial name
- INSPIRE (NCT06144840)
- Testing
- Dersimelagon
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 165 people
- Sponsor
- Tanabe Pharma America, Inc.
Carcinoid Syndrome, Carcinoid
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome.
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- NCT05361668
- Testing
- Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 36 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
HCV Infection
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-333 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of…
- Trial name
- NCT00768690
- Testing
- ABT-333, ketoconazole
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Abbott
Hepatitis
Analysis of Trends Over Time of Hepatitis Related Incidence in Panama
The purpose of this study is to analyze the incidence of baseline hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) together with the current frequency of the same outcome after introduction of…
- Trial name
- NCT01159951
- Testing
- Epidemiologic Surveillance System of the Ministry of Health of Panama
- Where
- Panama
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Metastatic Uveal Melanoma in the Liver
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
- Trial name
- NCT04935229
- Testing
- SD-101, Nivolumab, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- TriSalus Life Sciences, Inc.
Chronic Hepatitis C
Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)
This study will evaluate the technical feasibility of using fine needle aspiration (FNA) of liver tissue to obtain vaniprevir (MK-7009) liver pharmacokinetic (PK) data, working towards identifying a minimally invasive…
- Trial name
- NCT01678131
- Testing
- Vaniprevir 600 mg, Peg-IFN alfa-2b, Ribavirin
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.